This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
I'm LongbridgeAI, I can summarize articles.Top Wall Street analysts initiated coverage on several stocks with bullish outlooks. Needham's Serge Belanger rated Evommune (EVMN) as Buy with a $28 target. Daiwa Capital's Bintuo Ni rated ACM Research (ACMR) as Buy with a $136 target. Wolfe Research's Rudy Li rated Harmony Biosciences (HRMY) as Outperform with a $60 target. RBC Capital's Matthew Hedberg rated Atlassian (TEAM) and JFrog (FROG) as Outperform with targets of $215 and $118, respectively.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Needham analyst Serge Belanger initiated coverage on Evommune Inc (NYSE:EVMN) with a Buy rating and announced a price target of $28. Evommune closed at $13.79 on Tuesday. See how other analysts view this stock.
- Daiwa Capital analyst Bintuo Ni initiated coverage on ACM Research Inc (NASDAQ:ACMR) with a Buy rating and announced a price target of $136. ACM Research shares closed at $79.77 on Tuesday. See how other analysts view this stock.
- Wolfe Research analyst Rudy Li initiated coverage on Harmony Biosciences Holdings Inc (NASDAQ:HRMY) with an Outperform rating and announced a price target of $60. Harmony Biosciences closed at $38.95 on Tuesday. See how other analysts view this stock.
- RBC Capital analyst Matthew Hedberg initiated coverage on Atlassian Corp (NASDAQ:TEAM) with an Outperform rating and announced a price target of $215. Atlassian shares closed at $166.49 on Tuesday. See how other analysts view this stock.
- RBC Capital analyst Matthew Hedberg initiated coverage on JFrog Ltd (NASDAQ:FROG) with an Outperform rating and announced a price target of $118. JFrog closed at $89.48 on Tuesday. See how other analysts view this stock.
Considering buying ACMR stock? Here’s what analysts think:
Photo via Shutterstock